Clinical Trial Update: A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease [Phase 3]

View source ↗

Summary

A Phase 3 study assessing safety, disease activity, and pharmacokinetics of intravenous and subcutaneous risankizumab in pediatric Crohn's disease; the trial is…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease

Drugs mentioned

• SKYRIZI (risankizumab-rzaa)

Snippet

Sponsor: AbbVie | Conditions: Crohn's Disease | Phase 3 | Status: RECRUITING